<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM25803-0M0-YV-JKF"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S2345 IS: Short on Competition Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-07-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 2345</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250717">July 17, 2025</action-date><action-desc><sponsor name-id="S311">Ms. Klobuchar</sponsor> (for herself, <cosponsor name-id="S346">Mr. Lee</cosponsor>, <cosponsor name-id="S253">Mr. Durbin</cosponsor>, and <cosponsor name-id="S153">Mr. Grassley</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause"><section section-type="section-one" id="S1"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Short on Competition Act</short-title></quote>.</text></section><section id="idC0C577BB3B00443DB5F889894373C8FA"><enum>2.</enum><header>Temporary importation of prescription drugs</header><subsection id="id571525EF3E31413B82DFFADA444B8D6B"><enum>(a)</enum><header>Temporary importation</header><text>Section 506C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c">21 U.S.C. 356c</external-xref>) is amended—</text><paragraph id="id76757D3614CF44ED92AD1336016282D2"><enum>(1)</enum><text>by redesignating subsections (h), (i), and (j) as subsections (i), (j), and (k) respectively; and</text></paragraph><paragraph id="id4EDDFEDCC26A4A909E309AAF23176677"><enum>(2)</enum><text>by inserting after subsection (g) the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="idA369FE63FBD34553A8EE71C2609CE3E0"><subsection id="idFF642D356DD445F08805F4945849669F"><enum>(h)</enum><header>Temporary importation authority</header><paragraph id="idA1D6F7A5A5CF4419964DA41739A2A6D6"><enum>(1)</enum><header>In general</header><text>If, based on notifications described in subsection (a) or any other relevant information, the Secretary concludes that there is, or is likely to be, a drug shortage of a drug described in subsection (a), except as provided in paragraph (3), the Secretary shall authorize importation of such drug for a period of up to 3 years if—</text><subparagraph id="idE32F48A02DD5483DA225D900B58B7A9A"><enum>(A)</enum><text>the drug is a drug subject to section 503(b)(1), including a combination product whose primary mode of action is that of a drug as determined under section 503(g)(1)(D)(i), other than a drug described in subparagraphs (A) through (F) of section 804(a)(3);</text></subparagraph><subparagraph id="id0F673933076E4C069D43EAC781A2081B"><enum>(B)</enum><text>the drug is authorized to be lawfully marketed in one or more of the countries included in the list under section 802(b)(1);</text></subparagraph><subparagraph id="id8B8CBBB434454C2086225C0E3189DAD9"><enum>(C)</enum><text>the imported drug has the same active ingredient as the drug for which there is a shortage with respect to manufacturers in the United States;</text></subparagraph><subparagraph id="id560687170B2F47EB813D128FA7EC50E4"><enum>(D)</enum><text>the manufacturer certifies to the Secretary that it intends to seek approval of the drug under section 505(j); and</text></subparagraph><subparagraph id="idA41A013D093640D08F1C08C792104A53"><enum>(E)</enum><text>an importer (as defined in section 804(a)) files with the Secretary information—</text><clause id="idF47FA7EA4C684C748375867A6ADCEEC9"><enum>(i)</enum><text>attesting that the requirements under subparagraphs (A) through (D) are satisfied;</text></clause><clause id="id0DC299A9EFFE46CAB55AFBF06F998613"><enum>(ii)</enum><text>identifying the drug the importer proposes to import and the manufacturer from whom the importer proposes to import such drug; and</text></clause><clause id="idE1F979A031454C98802CCC57DAEF88D2"><enum>(iii)</enum><text>requesting authority to import the drug.</text></clause></subparagraph></paragraph><paragraph id="id95BC107BFB07442BB58A688FB2F1109C"><enum>(2)</enum><header>Beginning date of importation</header><text>Except as provided in paragraph (3), if all of the conditions under paragraph (1) are met, the Secretary shall authorize importation of a drug in accordance with such paragraph beginning not later than 60 days after receipt of the information under paragraph (1)(E).</text></paragraph><paragraph id="id3D1A0B34A31345BF8F92FF5BDF2CB4CF"><enum>(3)</enum><header>Discretionary denial of importation</header><text>The Secretary may deny importation of a drug otherwise qualified for importation under paragraph (1) if the Secretary determines that—</text><subparagraph id="idED484BD272614F798069AD34549F897C"><enum>(A)</enum><text>the drug is not safe and effective;</text></subparagraph><subparagraph id="idCF865B66919E407FA48E31CEA88EED02"><enum>(B)</enum><text>the drug is used in conjunction with a device for which there is no reasonable assurance of safety and effectiveness; or</text></subparagraph><subparagraph id="id7A7EB1B4CC134757B9B2BB9102EF56E3"><enum>(C)</enum><text>the authorization to market the drug in one or more of the countries included in the list under section 802(b)(1) has been rescinded or withdrawn because of any concern relating to the safety or effectiveness of the drug.</text></subparagraph></paragraph><paragraph id="id99B032B18C4F4A37BC971094DC3AD2ED"><enum>(4)</enum><header>Termination of authority</header><text>The authority to import a drug pursuant to paragraph (1) shall terminate after 3 years, or when the drug shortage no longer applies, whichever occurs first.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="id28B35940380E4FFF9FBE10DA64395A1D"><enum>(b)</enum><header>Marginally competitive drug markets</header><text display-inline="yes-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>) is amended by inserting after section 506C–1 the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="idB509EE30482B4FDBB3001DD679AC2E8F"><section id="id5FF2E9C75F324115A1BF2A2028C69D85"><enum>506C–2.</enum><header>Marginally competitive drug markets</header><subsection id="id939D8A7AEF3B4933AD5E9F0F3CC91359"><enum>(a)</enum><header>In general</header><text>If the Secretary determines under subsection (b) that a marginally competitive market exists with respect to an applicable drug, the Secretary—</text><paragraph id="idEB3383602D1B45FBA3C8DE1B51F7903E"><enum>(1)</enum><text>shall treat such marginally competitive market as creating a drug shortage only for purposes of subsections (g) and (h) of section 506C; and</text></paragraph><paragraph id="idE77D04C6970642E8BF7131A6F7D17EC0"><enum>(2)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="idBD8CF1A211C246978F48ECEA9E7743CA"><enum>(A)</enum><text>may expedite the review of applications and inspections with respect to the drug in accordance with section 506C(g); and</text></subparagraph><subparagraph id="id1A4D4C3FA58F404EB7EDD3C800A11808" indent="up1"><enum>(B)</enum><text>shall authorize importation of the drug in accordance with section 506C(h).</text></subparagraph></paragraph></subsection><subsection id="idEDB5DF2B9F8E4CC7AAFD876FA07A015E"><enum>(b)</enum><header>Determination of marginally competitive market</header><paragraph id="id610DD8793B4043BD912605D4F63B912A"><enum>(1)</enum><header>In general</header><text>The Secretary shall determine that a marginally competitive market exists with respect to an applicable drug if—</text><subparagraph id="idA700FE2D9E1840D49849F63A5EECE347"><enum>(A)</enum><text>for at least 2 consecutive months prior to the determination, fewer than 5 drugs approved under section 505(c) (referred to in this paragraph as the ‘applicable listed drug’) or under section 505(j) that reference the applicable listed drug were commercially available in the United States;</text></subparagraph><subparagraph id="id7ED40CCC6A814669AC56FF846F91B6BC"><enum>(B)</enum><text>the applicable listed drug was approved at least 10 years before such determination; and</text></subparagraph><subparagraph id="id33AA766D09EE439B9F38F9557222FF89"><enum>(C)</enum><text>each patent which claims an active ingredient of the applicable listed drug has expired.</text></subparagraph></paragraph><paragraph commented="no" id="ida439557e5c9f44c58acd576e66544e71"><enum>(2)</enum><header>Commercially available</header><subparagraph commented="no" id="id07F582AA4B464F77A274A9544AEBFCC7"><enum>(A)</enum><header>In general</header><text>For purposes of paragraph (1)(A), a drug is not commercially available in the United States if—</text><clause commented="no" id="id7020A94AA51441D68598A200045CA379"><enum>(i)</enum><text>the holder of an application approved under subsection (c) or (j) of section 505 has publicly announced that it has discontinued the manufacturing of the drug;</text></clause><clause commented="no" id="id1BA859D6C2F647B8A00DE649594AE2AF"><enum>(ii)</enum><text>a drug approved under subsection (c) or (j) of section 505 has been withdrawn or discontinued; or</text></clause><clause commented="no" id="idB0B0838B067842E089D8442E398281D9"><enum>(iii)</enum><text>the Secretary has any other reasonable basis to conclude that a drug approved under subsection (c) or (j) of section 505 is not competitively relevant.</text></clause></subparagraph><subparagraph commented="no" id="idF8C218004AF348A3B9218CA9A9F940AC"><enum>(B)</enum><header>Holder of approved application</header><text>In determining whether 5 drugs are commercially available under paragraph (1)(A), in the case of a single person who is the holder of more than one application approved as described in paragraph (1)(A) with respect to an applicable drug, only one such drug shall be considered to be commercially available.</text></subparagraph></paragraph></subsection><subsection commented="no" id="id4585F9BEF03D43E1B9F162BE4757CE8E"><enum>(c)</enum><header>Applicable drug</header><text>In this section, the term <term>applicable drug</term> means a drug that is not a radio pharmaceutical drug product or any other product as designated by the Secretary.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="id98E61DD44E874A769DB03E3C68437E11"><enum>(c)</enum><header>Annual reporting on drug shortages</header><text>Section 506C–1(a)(5)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c-1">21 U.S.C. 356c–1(a)(5)(B)</external-xref>) is amended—</text><paragraph id="idF7F279FC856245CCB56089B1E430B282"><enum>(1)</enum><text>in clause (i), by striking <quote>; and</quote> and inserting <quote>;</quote>;</text></paragraph><paragraph id="idAFA549AFD64B42A090AB8C83A772C046"><enum>(2)</enum><text>in clause (ii), by adding <quote>and</quote> after the semicolon; and</text></paragraph><paragraph id="id4A433631D8824B169BC4EAE0208B4721"><enum>(3)</enum><text>by inserting after clause (ii) the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id46993A3B334241D4B712FFA2AA84436B"><clause id="idD225FE591D634731861D6A8758C35747" indent="up1"><enum>(iii)</enum><text>the number of drugs authorized for temporary importation under section 506C(h);</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section></legis-body></bill> 

